Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elafibranor for Hepatic Lipid Composition in Nonalcoholic Fatty Liver
2019-000645-12Phase 2Terminated
- Sponsor
- Genfit
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of elafibranor in metabolic dysfunction-associated steatotic liver disease (MASLD) (2 arms), sponsored by Genfit. Primary endpoint: Relative amount of saturated fatty acids in the liver (%SFA). Started Jul 2019; status: terminated.
02
Drugs
elafibranor
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on 2019-000645-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000645-12.